Raymond E, et al. - Given that sunitinib led to a significant increase in progression- free survival (PFS) vs placebo in patients with pancreatic neuroendocrine tumors (panNETs) in a phase 3 study, researchers intended in this ongoing, open-label, phase 4 trial to determine the efficacy and safety of sunitinib in patients with well-differentiated panNETs. For this investigation, patients with progressive, advanced unresectable/metastatic, well-differentiated panNETs received continuous sunitinib 37.5 mg once daily. This phase 4 trial found sunitinib to be an effective and safe treatment option in subjects with advanced/metastatic, well-differentiated, unresectable panNETs, and supported the phase 3 study outcomes. They found that adverse events (AEs) were consistent with the known safety profile of sunitinib, with neutropenia (53.8%), diarrhea (46.2%), and leukopenia (43.4%) being the most common treatment-related AEs.